Lilly Investing Billions More Into US Manufacturing Sites
The Pro DeSantis News homepage has 60 new headlines every 24 hours - click here to see it.
Donald Trump’s economic policies are working.
Eli Lilly is committing another $4.5 billion in investment to its manufacturing sites in Indiana.
It has already committed to spending over $50 billion to bolster its manufacturing in the United States.
Since the start of the decade, Eli Lilly has committed to spend more than $50 billion to bolster its United States manufacturing capabilities. But even that’s not enough to meet the needs of the rapidly growing pharma giant.
On Wednesday, Lilly said that it has earmarked another $4.5 billion to further build up two of three planned production facilities in Lebanon, Indiana, some 28 miles northwest of Lilly’s headquarters in Indianapolis. The company revealed the new investment at a ribbon cutting ceremony for its genetic medicine plant in Lebanon, the first of the three new facilities at the site to become operational.
Of the sum Lilly has pledged to spend for its domestic manufacturing in this decade, more than $21 billion has been allocated for the buildup in its home state. Lilly’s “evolving pipeline” and shifts in the anticipated demand for its products dictated the additional funding, the company said.
…
Since he took office last year, President Donald Trump has used the threat of tariffs in a bid to drive manufacturing commitments back to the U.S., with many large drugmakers—including Johnson & Johnson, Novartis, Roche, Gilead, Bristol Myers Squibb and AstraZeneca—announcing investments. In all, the pledges came to $370 billion in 2025, according to a report from DPR Construction.
Lilly CEO said, “When our Lebanon API site opens in 2027, it will be the largest API production site in U.S. history, a commitment we chose to build here, at home.”
Governor Mike Braun celebrated the news, saying, “With this investment in Lebanon and across the state, Indiana is reinforcing its position as a prime destination for life sciences and advanced manufacturing, spanning innovation, production and global distribution.”
“Lilly’s legacy of firsts in Indiana continues today—and the best measure of that legacy is what we do next,” said David A. Ricks, Lilly chair and CEO. “From genetic medicines that could one day prevent disease at its source, to Foundayo, a pill making weight loss treatment accessible to millions, we are not just discovering the medicines of the future—we are building the world’s most advanced plants to make them. When our Lebanon API site opens in 2027, it will be the largest API production site in U.S. history, a commitment we chose to build here, at home.”
“This expansion reflects the strength of a long-standing partnership between Lilly and the state of Indiana – one that continues to deliver real results for Hoosiers,” said Governor Mike Braun. “With this investment in Lebanon and across the state, Indiana is reinforcing its position as a prime destination for life sciences and advanced manufacturing, spanning innovation, production and global distribution. Together, we are helping lead the future of medicine while creating high-quality jobs and new opportunities for our communities.”
Lilly’s manufacturing investment extends well beyond its campus walls. According to a report that will be released next week by Indiana University’s Kelley School of Business, Indiana Business Research Center, “Measuring Lilly’s Economic and Civic Contributions in Indiana,” Lilly accounts for 70% of Indiana’s pharmaceutical GDP and every Lilly job supports more than two additional jobs across the state. Further, the company estimates that for every dollar it spends in the area, up to four dollars in additional local economic activity is generated.
